## IDXX: IDEXX Laboratories, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -4.5% below STRENGTH zone (4.0-10.0%); PEG 4.22 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($659.80)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. iSAM Funds UK Ltd Takes $1.85 Million Position in IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251209T150814 | Somewhat-Bullish | Relevance: 100%
-  iSAM Funds UK Ltd has initiated a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX), acquiring 3,448 shares valued at approximately $1.85 million during the second quarter. This move contributes to the substantial institutional ownership of IDEXX, which now stands at about 87.84%. The company recently reported strong Q3 earnings, surpassing analyst estimates, and provided positive FY2025 guidance, with a consensus analyst price target of $763.50 indicating a "Moderate Buy" rating.

**2. Amundi Has $366.69 Million Stake in IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251207T050844 | Somewhat-Bullish | Relevance: 99%
-  Amundi reduced its stake in IDEXX Laboratories (NASDAQ:IDXX) by 6.6% to 675,672 shares, valued at $366.69 million, as of the second quarter. The company maintains a "Moderate Buy" consensus rating from analysts with an average price target of $730.50, and recently beat quarterly earnings and revenue estimates. An EVP also reduced her holdings by over 30% in a recent transaction.

**3. IDEXX Laboratories, Inc. (NASDAQ:IDXX) Given Consensus Rating of "Moderate Buy" by Brokerages**
- Source: MarketBeat | 20251209T070825 | Bullish | Relevance: 99%
- IDEXX Laboratories, Inc. (NASDAQ:IDXX) has received a consensus "Moderate Buy" rating from eleven brokerages, with an average 12-month price target of $763.50. The company recently exceeded quarterly earnings estimates, reporting $3.22 EPS against an expected $3.14, and generated $1.11 billion in revenue, beating forecasts of $1.07 billion. Insider selling by EVP Nimrata Hunt (9,425 shares at $703.34) reduced her stake by 30.8%, while institutional investors hold a significant 87.84% of the company's stock.

**4. Barclays Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating, Raises Target Price to $850**
- Source: 富途牛牛 | 20251209T150752 | Bullish | Relevance: 98%
-  Barclays analyst Balaji Prasad has maintained a Buy rating on IDEXX Laboratories Inc (IDXX.US) and significantly increased the target price from $520 to $850. This adjustment reflects a strong continued outlook for the company, according to the analyst's data provided by TipRanks.

**5. IDEXX Laboratories, Inc. $IDXX Shares Purchased by California Public Employees Retirement System**
- Source: MarketBeat | 20251209T102318 | Somewhat-Bullish | Relevance: 97%
- The California Public Employees Retirement System increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.7% in the second quarter, bringing its total holdings to 148,408 shares valued at $79.6 million. Other institutional investors also adjusted their positions, while an IDEXX executive recently sold over 9,000 shares. The company reported strong Q3 earnings, exceeding analyst expectations, and has a consensus "Moderate Buy" rating from analysts.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $850 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($2.08M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+0.9%)
- Blackrock Inc.: 10.3% (-2.0%)
- State Street Corpora: 4.4% (-1.0%)
- Fundsmith LLP: 3.3% (-1.1%)
- Geode Capital Manage: 3.1% (+1.4%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.9% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 4.2x requires aggressive growth execution.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.22 signals overvaluation risk, limited margin of safety. Forward P/E 48.5x stretched relative to 12% growth. Quality metrics strong (ROE 65%, ROA 24%, margin 25%). Insider buying signal ($2.1M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $55.9B |
| Beta | 1.67 |
| 52W Range | $356.14 - $769.98 |
| Short Interest | 2.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.22 |
| Forward P/E | 48.5 |
| Current P/E | 54.2 |
| YoY Growth | 11.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -0.6% to -4.5% (-3.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.5pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.24x) but short-term weakness (below SMA20). MACD histogram bearish (-5.82), momentum weakening. RSI neutral at 47.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.46% (CS: 22) | Weak |
| RSI_14 | 47.4 | Neutral |
| MACD Histogram | -5.82 | Bearish |
| vs SMA20 | 0.976x | Below |
| vs SMA50 | 1.034x | Above |
| vs SMA200 | 1.244x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $699.06
- **Stop Loss:** $659.80 (5.6% risk)
- **Target:** $738.32 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 7
- **Position Value:** $4,893.42
- **Portfolio %:** 4.89%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-03 (Est: $2.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.14 | $3.40 | +8.3% |
| 2025Q2 | $3.30 | $3.63 | +10.0% |
| 2025Q1 | $2.85 | $2.96 | +3.9% |
| 2024Q4 | $2.40 | $2.62 | +9.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*